Kopran Limited — PPTs, 11-02-2025: Investor Presentation

**Financial Highlights:** For Q3 FY 2024-25, Kopran reported revenue from operations at ₹166.24 crore, showcasing a significant increase from ₹151.56 crore in Q2 FY 2024-25 and ₹158.92 crore in Q3 FY 2023-24. The EBITDA stood at ₹22.91 crore, up from ₹14.74 crore in the previous quarter, while net profit reached ₹10.40 crore compared to ₹7.38 crore in Q2.

**Strategic Initiatives and Growth Drivers:** The company continues to focus on R&D for developing high-value APIs and intermediates while enhancing capacity and compliance with global regulations. The strategic shift aims to reduce reliance on Chinese suppliers for raw materials, promoting self-sufficiency.

**Business Developments:** Developments include increasing exports and exploring new geographic markets. The operational metrics illustrate growth in core areas such as anti-diabetic and anti-infective APIs, supported by a robust product mix.

**Market Position and Competitive Advantage:** Kopran capitalizes on state-of-the-art manufacturing facilities with various international accreditations, positioning the company strongly in both regulated and non-regulated markets.

**Investor Implications:** With a positive outlook driven by improved financial performance and strategic initiatives to boost capacity and product offerings, investors should monitor Kopran's growth trajectory closely as the company navigates its expansion plans.